

Robert L Murphy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9065540/robert-l-murphy-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177
papers

8,424
citations

44
h-index

89
g-index

197
ext. papers

9,323
ext. citations

6.7
avg, IF

5.07
L-index

#	Paper	IF	Citations
177	Has Omicron Changed the Evolution of the Pandemic?. <i>JMIR Public Health and Surveillance</i> , 2022 ,	11.4	6
176	Comparison of Rapid Antigen Tests Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study. 2022 ,		2
175	Analyses of Kaposi Sarcoma trends among adults establishing initial outpatient HIV care in Nigeria: 2006-2017.. <i>Infectious Agents and Cancer</i> , 2022 , 17, 10	3.5	
174	Accelerated Epigenetic Age Among Women with Invasive Cervical Cancer and HIV-Infection in Nigeria.. <i>Frontiers in Public Health</i> , 2022 , 10, 834800	6	
173	Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab511	1	1
172	Latin America and the Caribbean SARS-CoV-2 Surveillance: Longitudinal Trend Analysis. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e25728	11.4	2
171	Surveillance of the Second Wave of COVID-19 in Europe: Longitudinal Trend Analyses. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e25695	11.4	9
170	SARS-CoV-2 Surveillance System in Canada: Longitudinal Trend Analysis. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e25753	11.4	3
169	The Interplay Between Policy and COVID-19 Outbreaks in South Asia: Longitudinal Trend Analysis of Surveillance Data. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e24251	11.4	2
168	SARS-CoV-2 Surveillance in the Middle East and North Africa: Longitudinal Trend Analysis. <i>Journal of Medical Internet Research</i> , 2021 , 23, e25830	7.6	7
167	SARS-CoV-2 Wave Two Surveillance in East Asia and the Pacific: Longitudinal Trend Analysis. <i>Journal of Medical Internet Research</i> , 2021 , 23, e25454	7.6	6
166	Surveillance Metrics of SARS-CoV-2 Transmission in Central Asia: Longitudinal Trend Analysis. <i>Journal of Medical Internet Research</i> , 2021 , 23, e25799	7.6	5
165	Short Communication: Genetic Variation in Human Proximal Promoter and Susceptibility to HIV-1 Infection in Mali, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 57-61	1.6	
164	Impact of the COVID-19 pandemic on global health research training and education. <i>Journal of Global Health</i> , 2020 , 10, 020366	4.3	3
163	Effect of Baseline Symptom Manifestations on Retention in Care and Treatment among HIV-Infected Patients in Nigeria. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020 , 19, 2325958220903575	1.7	0
162	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1272-1279	5.1	0
161	A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy. <i>Journal of Medical Internet Research</i> , 2020 , 22, e24248	7.6	14

160	Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e24286	7.6	12
159	A preprogram appraisal of factors influencing research productivity among faculty at college of medicine, University of Lagos. <i>Annals of African Medicine</i> , 2020 , 19, 124-130	1.7	1
158	From Creation to Evaluation: A Comprehensive Global Health Scholars Program for Graduate Medical Education Trainees. <i>Journal of Medical Education and Curricular Development</i> , 2020 , 7, 2382120520951821	2.3	0
157	HIV and development of epithelial cell abnormalities in women with prior normal cervical cytology in Nigeria. <i>Infectious Agents and Cancer</i> , 2020 , 15, 50	3.5	1
156	p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. <i>BMC Medical Genetics</i> , 2020 , 21, 206	2.1	1
155	Evaluation of Two HIV Rapid Diagnostic Tests in a Context of StrainsPGenetic Diversity in Mali. <i>AIDS Research and Human Retroviruses</i> , 2019 , 35, 145-149	1.6	2
154	Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2003-2008	5.1	1
153	DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2019 , 11, 145	7.7	17
152	C-THAN: A new research center for the development of point-of-care technology for HIV/AIDS 2019 , 2, 1-5		0
151	HIV status, age at cervical Cancer screening and cervical cytology outcomes in an opportunistic screening setting in Nigeria: a 10-year Cross sectional data analysis. <i>Infectious Agents and Cancer</i> , 2019 , 14, 43	3.5	4
150	Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy. <i>Aids</i> , 2019 , 33, 465-473	3.5	10
149	Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya. <i>Aids</i> , 2019 , 33, 1404-1406	3.5	1
148	Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1733-1738	11.6	8
147	miRNA-Processing Gene Methylation and Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 550-557	4	13
146	Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy103	1	3
145	Promoter methylation of PGC1A and PGC1B predicts cancer incidence in a veteran cohort. <i>Epigenomics</i> , 2018 , 10, 733-743	4.4	7
144	DNA Methylation of Telomere-Related Genes and Cancer Risk. <i>Cancer Prevention Research</i> , 2018 , 11, 511-522	3.2	8
143	Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: A retrospective cohort analysis. <i>Journal of Medicine in the Tropics</i> , 2018 , 20, 49-56	0.1	8

142	The problem of resistance in may be underestimated in Africa. <i>International Journal of Mycobacteriology</i> , 2018 , 7, 148-151	0.9	
141	Association between patient-reported HIV status and provider recommendation for screening in an opportunistic cervical Cancer screening setting in Jos, Nigeria. <i>BMC Health Services Research</i> , 2018 , 18, 885	2.9	2
140	High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali. <i>Pediatric Infectious Disease Journal</i> , 2017 , 36, e258-e263	3.4	18
139	Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
138	Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians. <i>Tropical Medicine and International Health</i> , 2017 , 22, 744-754	2.3	5
137	Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0183924	3.7	72
136	Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 298-302	3.1	11
135	Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria. <i>Infectious Agents and Cancer</i> , 2017 , 12, 34	3.5	4
134	Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1147-1151	5.1	9
133	Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 820-828	5.1	10
132	Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. <i>Clinical Infectious Diseases</i> , 2016 , 62, 512-8	11.6	10
131	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. <i>Aids</i> , 2016 , 30, 221-30	3.5	43
130	Cervical cancer survival in a resource-limited setting-North Central Nigeria. <i>Infectious Agents and Cancer</i> , 2016 , 11, 15	3.5	16
129	A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 731-8	5.1	8
128	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. <i>PLoS ONE</i> , 2016 , 11, e0160341	3.7	7
127	Perspectives for immunotherapy: which applications might achieve an HIV functional cure?. <i>Oncotarget</i> , 2016 , 7, 38946-38958	3.3	8
126	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. <i>Lancet HIV,the</i> , 2015 , 2, e82-91	7.8	27
125	Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. <i>Clinical Infectious Diseases</i> , 2015 , 61, 651-60	11.6	91

124	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1241-9	7	85
123	A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. <i>Aids</i> , 2015 , 29, 1775-83	3.5	59
122	Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7852-6	5.9	13
121	Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria--Implications for Care. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015 , 14, 355-9	1.7	9
120	Enhancement of health research capacity in Nigeria through north-south and in-country partnerships. <i>Academic Medicine</i> , 2014 , 89, S93-7	3.9	18
119	Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1370-6	5.1	13
118	High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology. <i>Infectious Agents and Cancer</i> , 2014 , 9, 36	3.5	7
117	HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. <i>PLoS ONE</i> , 2014 , 9, e85371	3.7	21
116	High-risk human papillomavirus among HIV-infected women with normal cervical cytology: a pilot study in Jos, Nigeria. <i>Archives of Gynecology and Obstetrics</i> , 2013 , 288, 1365-70	2.5	12
115	Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, Mali. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 182-6	1.6	12
114	Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 931-7	1.6	15
113	Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. <i>Journal of Medical Virology</i> , 2013 , 85, 8-15	19.7	11
112	Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013 , 12, 236-40	1.7	6
111	Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. <i>Clinical Infectious Diseases</i> , 2013 , 57, e189-92	11.6	23
110	Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. <i>Journal of Infectious Diseases</i> , 2013 , 208, 512-9	7	39
109	Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. <i>Aids</i> , 2013 , 27, 929-937	3.5	41
108	Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 323-30	3.1	37
107	Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 204-7	3.1	10

106	Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 65-79	4	10
105	Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2943-8	5.1	28
104	Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. <i>AIDS Research and Treatment</i> , 2012 , 2012, 703604	2.3	11
103	Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1443-7	7	17
102	Dolutegravir for the treatment of HIV. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 523-30	5.9	57
101	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. <i>Aids</i> , 2012 , 26, 1231-41	3.5	95
100	Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 293-6	3.1	3
99	Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. <i>PLoS ONE</i> , 2012 , 7, e30396	3.96	37
98	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011 , 25, 27-36	3.5	37
97	Predictors of atypical squamous cell of undetermined significance cervical cytology with high-risk human papilloma virus genotypes. <i>Archives of Gynecology and Obstetrics</i> , 2011 , 283, 343-8	2.5	8
96	A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. <i>Journal of NeuroVirology</i> , 2011 , 17, 438-47	3.9	35
95	Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. <i>Future Virology</i> , 2011 , 6, 157-177	2.4	34
94	Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011 , 23, 775-85	2.2	48
93	Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1283-90	11.6	112
92	Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1191-201	7	133
91	Immunovirological and Biochemical Changes in Nigerian Patients with Hepatitis B Coinfection on Antiretroviral Therapy. <i>World Journal of AIDS</i> , 2011 , 01, 31-36	0.3	
90	Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2445-9	5.1	14
89	Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1686-96	7	99

88	Assessing the virologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 85-92	3.1	62
87	Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. <i>Drugs</i> , 2010 , 70, 1629-42	12.1	21
86	Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 563-5	3.1	3
85	Chicago medical response to the 2010 earthquake in Haiti: translating academic collaboration into direct humanitarian response. <i>Disaster Medicine and Public Health Preparedness</i> , 2010 , 4, 169-73	2.8	12
84	Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. <i>Aids</i> , 2010 , 24, 885-90	3.5	40
83	Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. <i>Antiviral Therapy</i> , 2010 , 15, 185-92	1.6	11
82	Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. <i>Advances in Therapy</i> , 2010 , 27, 1-16	4.1	16
81	Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. <i>Current HIV Research</i> , 2010 , 8, 194-8	1.3	16
80	Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. <i>Therapeutics and Clinical Risk Management</i> , 2009 , 5, 331-40	2.9	10
79	Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 1244-50	5.1	41
78	A step ahead on the HIV collaboratory. <i>Science</i> , 2009 , 324, 1264-5	33.3	4
77	Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1268-73	11.6	92
76	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. <i>Aids</i> , 2009 , 23, 817-24	3.5	193
75	Management of antiretroviral failure and resistance in developing countries. <i>Current Opinion in HIV and AIDS</i> , 2009 , 4, 538-44	4.2	10
74	Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 228-34	3.1	33
73	Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 60-4	3.1	35
72	Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 569-76	15.1	240
71	Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 464-471	4.9	27

70	Class-sparing regimens for initial treatment of HIV-1 infection. <i>New England Journal of Medicine</i> , 2008 , 358, 2095-106	59.2	575
69	Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naïve patients. <i>Aids</i> , 2008 , 22, 2212-4	3.5	21
68	Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 1167-74	1.6	5
67	Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2008 , 9, 1-10		51
66	Increased cardiovascular risk in HIV infection: drugs, virus and immunity. <i>Aids</i> , 2008 , 22, 1625-7	3.5	11
65	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). <i>Aids</i> , 2008 , 22, 1313-22	3.5	70
64	The marriage of science and optimized HIV care in resource-limited settings. <i>Aids</i> , 2008 , 22, 2227-30	3.5	4
63	Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa. <i>Cytometry Part B - Clinical Cytometry</i> , 2008 , 74 Suppl 1, S11-8	3.4	13
62	Adherence to antiretroviral therapy in resource-limited settings: everything matters. <i>Aids</i> , 2007 , 21, 1041-3	3.3	13
61	Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. <i>Clinical Infectious Diseases</i> , 2007 , 44, 749-54	11.6	32
60	Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2007 , 6, 188-97		2
59	Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46 Suppl 1, S1-2	3.1	7
58	Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. <i>HIV Clinical Trials</i> , 2007 , 8, 213-20		32
57	Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 304-10	3.1	58
56	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 769-81	27.4	173
55	Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. <i>Ophthalmology</i> , 2005 , 112, 771-9	7.3	76
54	Reply to Phillips. <i>Clinical Infectious Diseases</i> , 2005 , 40, 1380-1381	11.6	1
53	Transient viremia in HIV-infected patients and use of plasma preparation tubes. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1671-4	11.6	49

52	Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 689-95	1.6	11
51	Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. <i>Antiviral Therapy</i> , 2005 , 10, 13-28	1.6	9
50	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. <i>Antiviral Therapy</i> , 2005 , 10, 13-28	1.6	13
49	Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1500-6	11.6	30
48	Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. <i>Aids</i> , 2004 , 18, 775-9	3.5	86
47	Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. <i>New England Journal of Medicine</i> , 2004 , 350, 1850-61	59.2	429
46	Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. <i>PLoS Medicine</i> , 2004 , 1, e19	11.6	176
45	Evaluating therapeutic vaccines in patients infected with HIV. <i>Expert Review of Vaccines</i> , 2004 , 3, S169-77	3.2	11
44	Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 684-92	3.1	80
43	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , 2003 , 17, 691-8	3.5	104
42	Defining the toxicity profile of nevirapine and other antiretroviral drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34 Suppl 1, S15-20	3.1	21
41	Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. <i>New England Journal of Medicine</i> , 2003 , 349, 2293-303	59.2	291
40	Reviving Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, S43-52	3.1	4
39	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. <i>Aids</i> , 2003 , 17, 987-99	3.5	131
38	Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. <i>Aids</i> , 2003 , 17, 2603-14	3.5	140
37	Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. <i>Journal of Virology</i> , 2003 , 77, 12336-45	6.6	141
36	Reviving protease inhibitors: new data and more options. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33 Suppl 1, S43-52; quiz S53, S55-6	3.1	4
35	Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management. <i>Aids Reader</i> , 2003 , 13, S12-8		

34	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 685-93	1.6	170
33	The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). <i>Journal of Infectious Diseases</i> , 2002 , 186, 198-204	7	39
32	The AIDS autopsy spleen: a comparison of the pre-anti-retroviral and highly active anti-retroviral therapy eras. <i>Modern Pathology</i> , 2002 , 15, 406-12	9.8	11
31	Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. <i>Journal of Infectious Diseases</i> , 2002 , 186, 1013-8	7	4
30	Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. <i>Journal of Infectious Diseases</i> , 2002 , 185, 599-607	7	155
29	Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2002 , 186, 1092-7	7	63
28	Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. <i>Aids</i> , 2002 , 16, 757-65	3.5	3
27	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. <i>Aids</i> , 2002 , 16, 387-96	3.5	32
26	Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. <i>American Journal of Ophthalmology</i> , 2002 , 133, 48-61	4.9	124
25	A prospective study of discontinuing primary and secondary <i>Pneumocystis carinii</i> pneumonia prophylaxis after CD4 cell count increase to > 200 x 10 ⁶ /l. <i>Aids</i> , 2001 , 15, 1509-15	3.5	21
24	Skin test reactivity and cellular immune responses to <i>Mycobacterium avium</i> sensitin in AIDS patients at risk for disseminated <i>M. avium</i> infection. <i>Vaccine Journal</i> , 2001 , 8, 1277-8		6
23	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. <i>Aids</i> , 2001 , 15, 2407-14	3.5	180
22	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. <i>Aids</i> , 2001 , 15, 591-9	3.5	16
21	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. <i>Aids</i> , 2001 , 15, F1-9	3.5	175
20	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). <i>Aids</i> , 2000 , 14, 1601-10	3.5	65
19	Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 284, 183-9	27.4	130
18	Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. <i>Aids</i> , 2000 , 14, 1553-61	3.5	17
17	Introduction. <i>Clinical Infectious Diseases</i> , 2000 , 30 Suppl 2, S95	11.6	

16	Lopinavir. <i>Drugs</i> , 2000 , 60, 1380-1381	12.1	1
15	The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. <i>Aids</i> , 2000 , 14, 463-5	3.5	32
14	A family history study of male sexual orientation using three independent samples. <i>Behavior Genetics</i> , 1999 , 29, 79-86	3.2	65
13	Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999 , 22, 39-48		25
12	Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. <i>Aids</i> , 1999 , 13, 685-94	3.5	38
11	Atovaquone compared with dapson for the prevention of <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , 1998 , 339, 1000-07	59.2	145
10	Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. <i>Journal of Pain and Symptom Management</i> , 1997 , 14, 7-14	4.8	162
9	Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. <i>American Journal of Ophthalmology</i> , 1994 , 117, 776-82	4.9	17
8	Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. <i>Journal of Infectious Diseases</i> , 1993 , 167, 1184-8	7	75
7	Salvage therapy with clindamycin/primaquine for <i>Pneumocystis carinii</i> pneumonia. <i>Clinical Infectious Diseases</i> , 1992 , 14, 183-8	11.6	47
6	Aerosol pentamidine prophylaxis following pneumocystis carinii pneumonia in AIDS patients: Results of a blinded dose-comparison study using an ultrasonic nebulizer. <i>American Journal of Medicine</i> , 1991 , 90, 418-426	2.4	19
5	Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. <i>New England Journal of Medicine</i> , 1990 , 322, 941-9	59.2	1113
4	Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1989 , 24, 591-604	5.1	9
3	Corticosteroids, cytotoxic agents, and infection 563-566		
2	Corticosteroids, Cytotoxic Agents, and Infection 605-610		2
1	SARS-CoV-2 Surveillance System in Canada: Longitudinal Trend Analysis (Preprint)		1